These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 31760317)
1. Aldoxorubicin-loaded nanofibers are cytotoxic for canine mammary carcinoma and osteosarcoma cell lines in vitro: A short communication. Stokol T; Wan C; Blakely R; Bellat V; Law B Res Vet Sci; 2020 Feb; 128():86-89. PubMed ID: 31760317 [TBL] [Abstract][Full Text] [Related]
2. A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro. Rathore K; Cekanova M Drug Des Devel Ther; 2015; 9():5323-35. PubMed ID: 26451087 [TBL] [Abstract][Full Text] [Related]
3. The effects of baicalein on canine osteosarcoma cell proliferation and death. Helmerick EC; Loftus JP; Wakshlag JJ Vet Comp Oncol; 2014 Dec; 12(4):299-309. PubMed ID: 23228048 [TBL] [Abstract][Full Text] [Related]
4. Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines. Ong SM; Yamamoto H; Saeki K; Tanaka Y; Yoshitake R; Nishimura R; Nakagawa T Jpn J Vet Res; 2017 Feb; 65(1):17-28. PubMed ID: 29791117 [TBL] [Abstract][Full Text] [Related]
5. The effects of sulforaphane on canine osteosarcoma proliferation and invasion. Rizzo VL; Levine CB; Wakshlag JJ Vet Comp Oncol; 2017 Sep; 15(3):718-730. PubMed ID: 27045198 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Kurzman ID; Shi F; Vail DM; MacEwen EG Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295 [TBL] [Abstract][Full Text] [Related]
7. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53. York D; Withers SS; Watson KD; Seo KW; Rebhun RB Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821 [TBL] [Abstract][Full Text] [Related]
8. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin. Abu Ajaj K; Graeser R; Kratz F Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402 [TBL] [Abstract][Full Text] [Related]
9. Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27. Bakirel T; Alkan FÜ; Üstüner O; Çinar S; Yildirim F; Erten G; Bakirel U J Vet Med Sci; 2016 May; 78(4):657-68. PubMed ID: 26822118 [TBL] [Abstract][Full Text] [Related]
10. Role of tissue factor expression in thrombin generation by canine tumor cells. Gruber EJ; Catalfamo JL; Stokol T Am J Vet Res; 2016 Apr; 77(4):404-12. PubMed ID: 27027841 [TBL] [Abstract][Full Text] [Related]
13. Aldoxorubicin for the treatment of soft tissue sarcoma. Sachdev E; Sachdev D; Mita M Expert Opin Investig Drugs; 2017 Oct; 26(10):1175-1179. PubMed ID: 28846045 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the protective effects of all-trans-astaxanthin on canine osteosarcoma cell lines. Wakshlag JJ; Balkman CA; Morgan SK; McEntee MC Am J Vet Res; 2010 Jan; 71(1):89-96. PubMed ID: 20043787 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Mita MM; Natale RB; Wolin EM; Laabs B; Dinh H; Wieland S; Levitt DJ; Mita AC Invest New Drugs; 2015 Apr; 33(2):341-8. PubMed ID: 25388939 [TBL] [Abstract][Full Text] [Related]
16. Calotropis procera (Aiton) Dryand (Apocynaceae) as an anti-cancer agent against canine mammary tumor and osteosarcoma cells. Rabelo AC; Borghesi J; Carreira ACO; Hayashi RG; Bessa F; Barreto RDSN; da Costa RP; Cantanhede Filho AJ; Carneiro FJC; Miglino MA Res Vet Sci; 2021 Sep; 138():79-89. PubMed ID: 34119813 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma. Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024 [TBL] [Abstract][Full Text] [Related]
18. The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines. Breitbach JT; Louke DS; Tobin SJ; Watts MR; Davies AE; Fenger JM Vet Comp Oncol; 2021 Jun; 19(2):362-373. PubMed ID: 33438820 [TBL] [Abstract][Full Text] [Related]
19. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Royals SR; Farese JP; Milner RJ; Lee-Ambrose L; van Gilder J Am J Vet Res; 2005 Nov; 66(11):1961-7. PubMed ID: 16334957 [TBL] [Abstract][Full Text] [Related]
20. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin. Yousefpour P; Ahn L; Tewksbury J; Saha S; Costa SA; Bellucci JJ; Li X; Chilkoti A Small; 2019 Mar; 15(12):e1804452. PubMed ID: 30756483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]